Avenzo Therapeutics Appoints Patrick Machado to Board of Directors
Slice of Healthcare Team
11/25/2024
Key Highlights
- Patrick Machado, J.D., brings 20+ years of biotech leadership experience to Avenzo Therapeutics.
- Former co-founder of Medivation, Inc., contributing to its $14B acquisition by Pfizer.
- Avenzo’s lead drug, AVZO-021, targets advanced solid tumors and metastatic breast cancer.
Source: Business Wire
Notable Quotes
“ Pat has extensive experience leading and working with biotech companies around the world, and I am excited to welcome him to our board. ”
Athena Countouriotis, M.D., Co-founder, President, and CEO at Avenzo
“ I look forward to working with my fellow board members and the executive team to advance the company’s growth and potentially bring new treatment options to cancer patients. ”
Patrick Machado, J.D., Board Member at Avenzo
